Individualized Therapy with Ranibizumab in Wet Age-Related XXXX .

@entity1 @entity1020 @entity7
Individualized treatment regimens may reduce @entity1 burden with satisfactory @entity1 outcomes in neovascular age-related @entity1020 . Intravitreal anti- @entity7 drugs are the current gold standard. Fixed monthly injections offer the best visual outcome but this regimen is not commonly followed outside clinical trials. A PRN regimen requires monthly visits where the @entity1 is treated in the presence of signs of lesion activity. Therefore, an early detection of reactivation of the disease with immediate retreatment is crucial to prevent visual acuity loss. Several trials suggest that "treat and extend" and other proactive regimens provide a reasonable approach. The rationale of the proactive regimens is to perform treatment anticipating relapses or recurrences and therefore avoid drops in vision while individualizing @entity1 followup. Treat and extend study results in significant direct medical cost savings from fewer treatments and office visits compared to monthly treatment. Current data suggest that, for one year, PRN is less expensive, but treat and extend regimen would likely be less expensive for subsequent years. Once a @entity1 is not a candidate to continue with treatment, he/she should be sent to an outpatient unit with adequate resources to follow nAMD @entity1 in order to reduce the burden of specialized ophthalmologist services.
